Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 1.00 |
| ▸ | MMP3 | P08254 | 17/20 | 1.00 |
| ▸ | MMP1 | P03956 | 17/20 | 1.00 |
| ▸ | MMP7 | P09237 | 15/20 | 1.00 |
| ▸ | MMP8 | P22894 | 2/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 2/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 1.00 |
| ▸ | FCER2 | P06734 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1844243 | 1.00 | MMP2 (1.00) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL13253247 | 1.00 | MMP2 (1.00) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4424468 | 0.91 | MMP2 (0.86) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4428170 | 0.88 | MMP2 (0.81) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4431907 | 0.87 | MMP2 (0.78) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4425335 | 0.87 | MMP2 (0.78) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4421723 | 0.87 | MMP2 (0.78) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4431974 | 0.87 | MMP2 (0.78) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL4423322 | 0.85 | MMP2 (0.75) | MMP2MMP3MMP1MMP7MMP8 | |
| SCHEMBL14081295 | 0.85 | MMP2 (0.73) | MMP2MMP3MMP1MMP7MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | MMP17, MMP25, TIMP3 | MMP2 7/4885MMP3 8/4885MMP1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.